// OVERVIEW
DeepMind spin-out focused on AI-driven drug discovery, led by Demis Hassabis.
Discussed in
- Google's AI Brain Drain, SpaceX's Huge Quarter, Airtable's 90% Collapse, US Data Fuels China AI
- SaaS Shudders After Airtable's Humbling Sale to Italian Grim Reaper Bending Spoons
- Decacorns are the new unicorns
- TBPN, Jack Altman, a16z, Now It’s Lightspeed's Media Move
- 💭 AI's messy middle
- The AI Trade Keeps on Giving as Cerebras, Nvidia & Market Indexes Soar
// RECENT MENTIONS
// SIGNALS
14 SIGNALS
01
mention·All In·AUGUST 8, 2026
Source→02
hire·Newcomer Newsletter·AUGUST 7, 2026
“Demis Hassabis was stepping back from his role as the CEO of DeepMind to become the division's Chair and Chief Scientist at Alphabet, letting him focus more on Google's AI biotech wing Isomorphic Labs.”
Source→03
mention·Training Data·AUGUST 4, 2026
“A lot of times folks think about Chai and Isomorphic in the same neighborhood. Isomorphic is developing drugs. You guys are enabling the existing industry to develop drugs more efficiently.”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.